A Slovakian institute has developed a new technology that allows to control dosing of factor VIII (a clotting factor) to haemophilic patients over and after surgery. It depends exclusively on the inherent characteristics of the patient dominant for the fate of factor VIII in the patients body and is independent from the route of factor VIII administration. They are open for license and/or joint venture.